RxDoctor Payments DataLook up a doctor →

Elise Wiesner, MD

Internal Medicine · Norman, OKNPI 1386626497

Payments from drug & device makers

$584,046in general payments, 2019–2025

Across 710 payments — averaging $822.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$457K
  • Bristol Myers Squibb$70K
  • Genentech, Inc.$21K
  • Eli Lilly$15K
  • Roche Products Limited$6K
  • AstraZeneca$4K
  • plus $11K from 49 others

What the payments were for

  • Food & beverage$10,73599%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$584,046 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$225,611
Medicare patients
387
Services billed
4,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$131,249
Austedo XrDeutetrabenazine21$118,139
JanuviaSitagliptin Phosphate89$99,556
JardianceEmpagliflozin42$61,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$47,926
EliquisApixaban48$43,247
Tresiba Flextouch U-100Insulin Degludec38$34,484
MounjaroTirzepatide29$33,234
FarxigaDapagliflozin Propanediol46$33,031
TrulicityDulaglutide22$27,528
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$5,535
PremproEstrogen,con/M-Progest Acet15$5,483
Candesartan Cilexetil51$5,206
VascepaIcosapent Ethyl13$5,114
SynthroidLevothyroxine Sodium58$5,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$647$131,249131 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$80$118,13921 claims
MerckJanuvia$230$99,55689 claims
Boehringer IngelheimJardiance$637$61,46142 claims
Lilly USA, LLCMounjaro, Trulicity$1,257$60,76151 claims
PfizerEliquis, Prempro$1,038$48,73063 claims
GSKTrelegy Ellipta$841$47,92665 claims
AstraZenecaFarxiga$3,865$33,03146 claims
AbbVieSynthroid$2,077$5,05258 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$3,904364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →